Trial Profile
A phase II bridging study recombinant protective antigen anthrax vaccine (SparVax)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2017
Price :
$35
*
At a glance
- Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- 23 Jan 2017 New trial record
- 19 Jan 2017 According to a PharmAthene media release, this study is anticipated to begin during the second half of 2017 with data anticipated during 2018.